Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals
CD Spinner, S Bell, H Einsele, C Tremblay… - Advances in …, 2024 - Springer
Abstract Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact. The emergence …
syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact. The emergence …
Serological response and immune‐related adverse events following COVID‐19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic …
Y Wang, D Chen, Y Pan, H Li, W Zhao… - Reviews in Medical …, 2024 - Wiley Online Library
With the popularity of Coronavirus disease 2019 (COVID‐19) vaccine and the development
of vaccination strategies, the impact of COVID‐19 vaccine on cancer patients receiving …
of vaccination strategies, the impact of COVID‐19 vaccine on cancer patients receiving …
[HTML][HTML] Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer …
A Mostaghim, S Minkove, J Aguilar-Company… - International Journal of …, 2024 - Elsevier
Objectives To date, studies have not provided definitive answers regarding whether
previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with …
previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with …
Immune checkpoint inhibitors and risk of immune-mediated adverse events: a cohort study comparing extended versus standard interval administration
A Lessard-Roy, R Marchand, P Lemieux… - Clinical and …, 2024 - Springer
The COVID-19 pandemic precipitated the implementation of extended interval immune
checkpoint inhibitors (ICIs) in an effort to limit hospital visits, but few studies have examined …
checkpoint inhibitors (ICIs) in an effort to limit hospital visits, but few studies have examined …